<SEC-DOCUMENT>0000059478-23-000160.txt : 20230427
<SEC-HEADER>0000059478-23-000160.hdr.sgml : 20230427
<ACCEPTANCE-DATETIME>20230427070250
ACCESSION NUMBER:		0000059478-23-000160
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230427
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230427
DATE AS OF CHANGE:		20230427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		23851817

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lly-20230427.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:0648555f-848d-4bf3-b068-d9d93f375df5,g:e4b507f7-8b41-4fa3-9cf2-cf8775bee485,d:5772fe5dc6664d57a7596c4a40096f9d--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:lly="http://www.lilly.com/20230427" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lly-20230427</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF80L2ZyYWc6MzYwYmRkNTdhZmI1NGZmYThkZTc2NWI3MjQyNjRkMDgvdGFibGU6NmE1MzBhYWJiZDFjNDIyOGJhNjZkYjQ5NTEwYzcxNjYvdGFibGVyYW5nZTo2YTUzMGFhYmJkMWM0MjI4YmE2NmRiNDk1MTBjNzE2Nl8yLTEtMS0xLTI0NjI1OQ_05aeaf74-1508-4fc2-bfb0-c70be6d9ce50">0000059478</ix:nonNumeric><ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF80L2ZyYWc6MzYwYmRkNTdhZmI1NGZmYThkZTc2NWI3MjQyNjRkMDgvdGFibGU6NmE1MzBhYWJiZDFjNDIyOGJhNjZkYjQ5NTEwYzcxNjYvdGFibGVyYW5nZTo2YTUzMGFhYmJkMWM0MjI4YmE2NmRiNDk1MTBjNzE2Nl81LTEtMS0xLTI0NjI1OQ_b69f4922-e3a5-4e5d-93ae-4c35f8de7678">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lly-20230427.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib841fae2ec0041df94d705b7c5c14954_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia053b0dde893464cb58e570dbaa02309_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i714a0c27150a4568b4850965bd5f6641_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2acc59ac3a0c401d9b6f057b8da86a38_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0b01fdf8cee4e8f9817ca496a034993_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie516118962284c77abd784c53b345cc4_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic889a2b0adaf47e9b220814578c43df0_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i500b5a8110364b38a2336189ed914378_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i529ddd44d0494587a58bf97eea7a37e5_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb727a34f7b546539b8a597247d52660_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa3feeb9856e4ce6833d755e771f1f07_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5772fe5dc6664d57a7596c4a40096f9d_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:1.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:8.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGV4dHJlZ2lvbjplZjNlMzcwZjgyNWE0MTQ2OTkyOGVjMmUyOTliYzlmNV8xMTg2_3473ab51-eac2-4d98-80f0-7c6a6e93d106">8-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:2.2pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:13.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGV4dHJlZ2lvbjplZjNlMzcwZjgyNWE0MTQ2OTkyOGVjMmUyOTliYzlmNV8xNTk_1f3870c5-141a-483e-b684-1d273264ae8c">April 27, 2023</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGV4dHJlZ2lvbjplZjNlMzcwZjgyNWE0MTQ2OTkyOGVjMmUyOTliYzlmNV8xMTg3_ce1947d2-0ff5-43ee-90e7-6ec5d91d095a">ELI LILLY AND COMPANY</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (Exact Name of Registrant as Specified in its Charter)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6NGJkNWY5MjkwNDRhNDg5M2I1ZjQ4OGNkZmI0YjNkMWQvdGFibGVyYW5nZTo0YmQ1ZjkyOTA0NGE0ODkzYjVmNDg4Y2RmYjRiM2QxZF8wLTAtMS0xLTI0NjI1OQ_ef7fc549-d913-49c4-ab40-8631fe5f0c8f">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6NGJkNWY5MjkwNDRhNDg5M2I1ZjQ4OGNkZmI0YjNkMWQvdGFibGVyYW5nZTo0YmQ1ZjkyOTA0NGE0ODkzYjVmNDg4Y2RmYjRiM2QxZF8wLTItMS0xLTI0NjI1OQ_27f7c0f6-4f0a-47c0-af22-2a9cc2a0fd46">001-06351</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6NGJkNWY5MjkwNDRhNDg5M2I1ZjQ4OGNkZmI0YjNkMWQvdGFibGVyYW5nZTo0YmQ1ZjkyOTA0NGE0ODkzYjVmNDg4Y2RmYjRiM2QxZF8wLTQtMS0xLTI0NjI1OQ_ce03be71-1b32-43a4-b321-f4fc61e76da6">35-0470950</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:21.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZThiOTFjNzE2NmJiNGE0YmI2ZmRlMjVhMDBjODMzMDEvdGFibGVyYW5nZTplOGI5MWM3MTY2YmI0YTRiYjZmZGUyNWEwMGM4MzMwMV8wLTAtMS0xLTI0NjI1OQ_94a1b355-cbab-4843-996f-4a1d1c16fbbf">Lilly Corporate Center</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZThiOTFjNzE2NmJiNGE0YmI2ZmRlMjVhMDBjODMzMDEvdGFibGVyYW5nZTplOGI5MWM3MTY2YmI0YTRiYjZmZGUyNWEwMGM4MzMwMV8xLTAtMS0xLTI0NjI1OQ_c22543e6-da87-4466-ab69-e43d8c4d1733">Indianapolis,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZThiOTFjNzE2NmJiNGE0YmI2ZmRlMjVhMDBjODMzMDEvdGFibGVyYW5nZTplOGI5MWM3MTY2YmI0YTRiYjZmZGUyNWEwMGM4MzMwMV8xLTEtMS0xLTI0NjI1OQ_8a9024dc-f2aa-44fa-a70d-fb327036027b">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZThiOTFjNzE2NmJiNGE0YmI2ZmRlMjVhMDBjODMzMDEvdGFibGVyYW5nZTplOGI5MWM3MTY2YmI0YTRiYjZmZGUyNWEwMGM4MzMwMV8xLTItMS0xLTI0NjI1OQ_8eea13da-ec4d-4e7e-93ba-3c7925a7eefc">46285</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGV4dHJlZ2lvbjplZjNlMzcwZjgyNWE0MTQ2OTkyOGVjMmUyOTliYzlmNV8xMTg4_f0eb0f41-0cbd-433e-9f10-7ad855c2052e">317</ix:nonNumeric>) <ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGV4dHJlZ2lvbjplZjNlMzcwZjgyNWE0MTQ2OTkyOGVjMmUyOTliYzlmNV8xMTg5_63b5004b-3a4b-45e3-bc9b-606c7b400aef">276-2000</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> (Former Name or Former Address, if Changed Since Last Report.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:13.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2.):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZTdkZjgyY2M1NzAyNGJlMDkwYzZhMjM5M2JiNmQ2MGUvdGFibGVyYW5nZTplN2RmODJjYzU3MDI0YmUwOTBjNmEyMzkzYmI2ZDYwZV8wLTAtMS0xLTI0NjI1OQ_5567bcc6-cb76-4fce-a7f0-187dc41eaec4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6YWRiNmVkNDA2YmQ1NDA4M2E1ZWY2ZGQyNTM1M2E0ZjIvdGFibGVyYW5nZTphZGI2ZWQ0MDZiZDU0MDgzYTVlZjZkZDI1MzUzYTRmMl8wLTAtMS0xLTI0NjI1OQ_8ffdd6a7-0ca9-45ef-a91b-b8b57b06438a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6MjBhMzM4MmI2NDYxNDFkYzgxNTcyMjFjNWQ3MzJhYzAvdGFibGVyYW5nZToyMGEzMzgyYjY0NjE0MWRjODE1NzIyMWM1ZDczMmFjMF8wLTAtMS0xLTI0NjI1OQ_02fd2e0c-984f-4f5e-bb00-a333b377bc4d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:2.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6YWM2OTZlMTIzMWE2NGVkZmIwNzc4NzNhOGNlNTNhNGMvdGFibGVyYW5nZTphYzY5NmUxMjMxYTY0ZWRmYjA3Nzg3M2E4Y2U1M2E0Y18wLTAtMS0xLTI0NjI1OQ_ee06fdd6-3521-4776-baf7-b1279cf092ed">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib841fae2ec0041df94d705b7c5c14954_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xLTAtMS0xLTI0NjI1OQ_c79791ea-60ee-4a52-9149-30277a8cc310">Common Stock (no par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib841fae2ec0041df94d705b7c5c14954_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xLTItMS0xLTI0NjI1OQ_ab1f3845-3dd3-4a1d-93fe-d2c04a58748d">LLY</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib841fae2ec0041df94d705b7c5c14954_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xLTQtMS0xLTI0NjI1OQ_26954b00-82c7-4f36-85ca-b161aeafb69b">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia053b0dde893464cb58e570dbaa02309_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8yLTAtMS0xLTI0NjI1OQ_19cb295b-137d-43f2-a73c-54ceaef0f582">7 1/8% Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia053b0dde893464cb58e570dbaa02309_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8yLTItMS0xLTI0NjI1OQ_a7d723ab-c804-488f-83f9-5d2efafc3200">LLY25</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia053b0dde893464cb58e570dbaa02309_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8yLTQtMS0xLTI0NjI1OQ_babc635f-4018-4e8e-8b95-022b2c8fd9b1">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i714a0c27150a4568b4850965bd5f6641_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8zLTAtMS0xLTI0NjI1OQ_c1c7f50c-60db-4f8a-b0fa-4c45ac50168d">1.625% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i714a0c27150a4568b4850965bd5f6641_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8zLTItMS0xLTI0NjI1OQ_fae0da6c-ae3a-499f-8dd2-dc5897a0e6d7">LLY26</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i714a0c27150a4568b4850965bd5f6641_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8zLTQtMS0xLTI0NjI1OQ_f654bfd2-1d48-4e89-8f43-81c3b59d42aa">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2acc59ac3a0c401d9b6f057b8da86a38_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl80LTAtMS0xLTI0NjI1OQ_e180bf71-a993-4e48-8529-c6393a02f4b1">2.125% Notes due 2030</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2acc59ac3a0c401d9b6f057b8da86a38_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl80LTItMS0xLTI0NjI1OQ_67b53ce6-7f3e-4a85-a51f-52561020fd74">LLY30</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2acc59ac3a0c401d9b6f057b8da86a38_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl80LTQtMS0xLTI0NjI1OQ_5226de6d-4e8a-46fe-9f79-cb4c6db1429e">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if0b01fdf8cee4e8f9817ca496a034993_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl81LTAtMS0xLTI0NjI1OQ_c478f30f-f717-438e-8a20-5f766df70e9d">0.625% Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if0b01fdf8cee4e8f9817ca496a034993_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl81LTItMS0xLTI0NjI1OQ_1f2dccc4-c393-46b1-b1de-f88f7adc2d23">LLY31</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if0b01fdf8cee4e8f9817ca496a034993_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl81LTQtMS0xLTI0NjI1OQ_283434a4-d479-487b-88d1-e79afde67dfb">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie516118962284c77abd784c53b345cc4_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl82LTAtMS0xLTI0NjI1OQ_f75a0195-1df4-4c2d-a9aa-abb02662b734">0.500% Notes due 2033</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie516118962284c77abd784c53b345cc4_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl82LTItMS0xLTI0NjI1OQ_6a199be1-0ae4-4368-9e9d-39e7565a4736">LLY33</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie516118962284c77abd784c53b345cc4_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl82LTQtMS0xLTI0NjI1OQ_3b9d2545-3576-4357-aecd-55dfcdf86bc1">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic889a2b0adaf47e9b220814578c43df0_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl83LTAtMS0xLTI0NjI1OQ_4bb9cd58-340b-4ece-9782-c0a04ce64f58">6.77% Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic889a2b0adaf47e9b220814578c43df0_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl83LTItMS0xLTI0NjI1OQ_914fc5a8-b67b-45b0-9bbb-3c08408fbd58">LLY36</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic889a2b0adaf47e9b220814578c43df0_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl83LTQtMS0xLTI0NjI1OQ_58fe7fa2-cb5e-48f8-a163-b1c0baa73887">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i500b5a8110364b38a2336189ed914378_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl84LTAtMS0xLTI0NjI1OQ_5839ad73-7ffb-40aa-bde8-111d7d15e3ad">1.625% Notes due 2043</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i500b5a8110364b38a2336189ed914378_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl84LTItMS0xLTI0NjI1OQ_0b145456-d978-417f-a8ad-db859afd0d92">LLY43</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i500b5a8110364b38a2336189ed914378_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl84LTQtMS0xLTI0NjI1OQ_b17ffb2a-685f-4ba9-9b52-225eb480c4b2">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i529ddd44d0494587a58bf97eea7a37e5_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl85LTAtMS0xLTI0NjI1OQ_2ea5f90c-f2aa-47bb-adef-9d6c867be347">1.700% Notes due 2049</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i529ddd44d0494587a58bf97eea7a37e5_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl85LTItMS0xLTI0NjI1OQ_da5492d2-2255-4589-a614-627fbdff8021">LLY49A</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i529ddd44d0494587a58bf97eea7a37e5_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl85LTQtMS0xLTI0NjI1OQ_f6504b53-3755-4fe8-8937-0c8586586365">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieb727a34f7b546539b8a597247d52660_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xMC0wLTEtMS0yNDYyNTk_dd0b21dc-b367-4f45-a5b8-1fa828f19aa6">1.125% Notes due 2051</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieb727a34f7b546539b8a597247d52660_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xMC0yLTEtMS0yNDYyNTk_ecc64802-d6a6-4488-8dac-d57bea302b66">LLY51</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieb727a34f7b546539b8a597247d52660_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xMC00LTEtMS0yNDYyNTk_14d54397-58dc-4a50-b6ff-76e38a0a52e2">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa3feeb9856e4ce6833d755e771f1f07_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xMS0wLTEtMS0yNDYyNTk_9591e090-adf1-4eb6-8f8e-ecb2216fd131">1.375% Notes due 2061</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa3feeb9856e4ce6833d755e771f1f07_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xMS0yLTEtMS0yNDYyNTk_fad0b3ae-aa79-4981-8fbe-2894f64e2948">LLY61</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa3feeb9856e4ce6833d755e771f1f07_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xMS00LTEtMS0yNDYyNTk_00005cef-0f32-43ef-8875-646f642d6c01">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGV4dHJlZ2lvbjplZjNlMzcwZjgyNWE0MTQ2OTkyOGVjMmUyOTliYzlmNV8xMTg1_8e216d32-98b8-4a4a-af77-4b42094ced19">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i5772fe5dc6664d57a7596c4a40096f9d_7"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated April&#160;27,&#160;2023, announcing the financial results of Eli Lilly and Company for the quarter ended March 31, 2023.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.745%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q123lillysalesandearningsp.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q123lillysalesandearningsp.htm">Press Release of Eli Lilly and Company, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q123lillysalesandearningsp.htm">April 27</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q123lillysalesandearningsp.htm">, 2023.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.707%"><tr><td style="width:1.0%"></td><td style="width:15.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.666%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ELI LILLY AND COMPANY</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Senior Vice President, Finance, and <br/>Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">April 27, 2023</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.01
<SEQUENCE>2
<FILENAME>q123lillysalesandearningsp.htm
<DESCRIPTION>EX-99.01
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icfb02474ee2542719995681d825190a1_1"></div><div style="min-height:103.68pt;width:100%"><div style="text-align:right"><img alt="logoa31.jpg" src="logoa31.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:112px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">April 27, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:700;line-height:100%">For Release&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Immediately </font></div><div><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Refer to&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Jordan Bishop&#59; jordan.bishop&#64;lilly.com&#59; (317) 473-5712 (Media)</font></div><div style="padding-left:36pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Joe Fletcher&#59; jfletcher&#64;lilly.com&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(317) 296-2884</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%"> (Investors)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:140%">Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Revenue in Q1 2023 decreased 11% driven by a $1.47 billion decline in revenue from COVID-19 antibodies. Excluding COVID-19 antibodies, revenue in Q1 2023 increased 10%, driven by volume growth from Mounjaro, Trulicity, Verzenio and Jardiance.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Pipeline progress included positive results in the tirzepatide Phase 3 SURMOUNT-2 study&#59; FDA approval of an expanded indication for Verzenio&#59; approval of mirikizumab in Japan&#59; and regulatory submissions of tirzepatide for obesity in the EU and lebrikizumab for atopic dermatitis in Japan.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">New Products</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">(i)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> contributed $573.6 million to revenue in Q1 2023, led by Mounjaro. Growth Products</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">(ii)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> revenue increased 18% to $4.56 billion in Q1 2023, led by Verzenio, Trulicity, Jardiance and Taltz.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Driven by the decline in COVID-19 antibodies revenue, Q1 2023 EPS decreased 29% to $1.49 on a reported basis and decreased 38% to $1.62 on a non-GAAP basis, both inclusive of $0.10 of acquired IPR&#38;D.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">2023</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> reported EPS guidance raised $0.28 to be in the range of $8.18 to $8.38 and non-GAAP EPS guidance raised $0.30 to be in the range of $8.65 to $8.85. </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:120%">(i) Lilly defines New Products as select products launched since 2022, which currently consist of Jaypirca and Mounjaro.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:120%">(ii) Lilly defines Growth Products as select products launched prior to 2022, which currently consist of Cyramza, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:120%">Emgality, Jardiance, Olumiant, Retevmo, Taltz, Trulicity, Tyvyt and Verzenio.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">INDIANAPOLIS, April 27, 2023 - Eli Lilly and Company (NYSE&#58; LLY) today announced its financial results for the first quarter of 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#34;Core business growth drove solid first-quarter financial results and a strong start for Lilly in 2023, which includes pipeline progress led by positive SURMOUNT-2 data for tirzepatide in obesity,&#34; said David A. Ricks, Lilly's chair and CEO. &#34;We also announced important price reductions to make insulin more affordable and accessible for people with diabetes, as well as a significant investment in </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Eli Lilly and Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#124; Lilly Corporate Center &#124; Indianapolis, Indiana 46285 &#124; U.S.A.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">manufacturing facilities. It is an exciting year for Lilly and we look forward to delivering more medicines for unmet health needs to more people around the world.&#34;</font></div><div id="icfb02474ee2542719995681d825190a1_4"></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Lilly has had numerous updates recently on key regulatory, clinical, business development and other events, including&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The announcement that tirzepatide achieved superior weight loss and met both co-primary objectives and all key secondary objectives compared to placebo at 72 weeks in the Phase 3 SURMOUNT-2 study&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The </font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">U.S. Food and Drug Administration's (FDA)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> approval of an expanded indication for Verzenio</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer at a high risk of recurrence&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Price reductions of 70% for the company's most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The FDA's issuance of a complete response letter for mirikizumab in ulcerative colitis, citing issues related to the proposed manufacturing of mirikizumab with no concerns about the clinical data package, safety or label&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The FDA's acceptance of the supplemental New Drug Application for Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> for children 10 years and older with type 2 diabetes&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The announcement that the company will invest an additional $1.6 billion at its two new manufacturing sites in Indiana, bringing the company&#8217;s total commitment to $3.7 billion and up to 700 new jobs&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The agreement to sell the rights of the olanzapine portfolio, including Zyprexa</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, to Cheplapharm Arzneimittel GmbH for $1.05 billion in cash upon regulatory approval and successful closing of the transaction, with an additional $305 million in cash upon the one year anniversary of closing and milestone payments of up to $50 million.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The agreement to sell the rights of Baqsimi</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> to Amphastar Pharmaceuticals, Inc. for $500 million in cash upon regulatory approval and successful closing of the transaction, with an </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;2</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">additional $125 million in cash upon the one year anniversary of closing and milestone payments of up to $450 million.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The collaboration with International Agencies Ltd. to increase patient access and improve affordability for high-quality insulin for nearly one million people living with diabetes in Bangladesh by 2030.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For additional information on important public announcements, visit the news section of Lilly's website.</font></div><div><font><br></font></div><div id="icfb02474ee2542719995681d825190a1_7"></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Financial Results</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.467%"><tr><td style="width:1.0%"></td><td style="width:44.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.013%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.013%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.232%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$ in millions, except <br>per share data</font></td><td colspan="15" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">First Quarter</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">% Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">$6,960.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">$7,810.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">(11)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Net Income &#8211; Reported</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,344.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,902.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">(29)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">EPS &#8211; Reported</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1.49</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">2.10</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">(29)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Net Income &#8211; Non-GAAP</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,463.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">2,372.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">(38)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">EPS &#8211; Non-GAAP</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1.62</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">2.62</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">(38)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">A discussion of the non-GAAP financial measures is included below under &#34;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited).&#34;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">First-Quarter Reported Results</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q1 2023, worldwide revenue was $6.96 billion, a decrease of 11% compared with Q1 2022, driven by a 5% decrease due to lower realized prices, a 4% decrease due to lower volume, and a 2% decrease from the unfavorable impact of foreign exchange rates. The decline in volume was driven by $1.47 billion in revenue from COVID-19 antibodies in Q1 2022</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> Excluding COVID-19 antibodies, revenue in Q1 2023 increased 10% and total worldwide volume increased 18%. New Products contributed $573.6 million to revenue in Q1 2023. Growth Products revenue increased </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;3</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">18% to $4.56 billion in Q1 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Revenue in the U.S. decreased 14% to $4.44 billion, driven by a 10% decrease in volume and a 5% decrease due to lower realized prices. The decline in volume was driven by $1.46 billion in revenue from COVID-19 antibodies in Q1 2022</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">. </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Excluding revenue from COVID-19 antibodies, revenue in the U.S. increased 19%, primarily driven by volume from Mounjaro</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Trulicity</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> and Verzenio, partially offset by decreased volume from Alimta</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> due to the loss of patent exclusivity. The lower realized prices in the U.S. were primarily driven by Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> and Trulicity.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Revenue outside the U.S. decreased 4% to $2.52 billion, driven by a 6% decrease from the unfavorable impact of foreign exchange rates and a 5% decrease due to lower realized prices, partially offset by a 7% increase in volume. The lower realized prices were primarily driven by the impact of government pricing in China from the volume-based procurement (VBP) for Humalog. The increase in volume outside the U.S. was largely driven by Verzenio and Jardiance and, to a lesser extent, Taltz</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Trulicity and Mounjaro, partially offset by a decrease in Cialis</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> volume due to the Q1 2022 sales of the company's rights to Cialis in Taiwan and Saudi Arabia.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Gross margin decreased 7% to $5.33 billion in Q1 2023. Gross margin as a percent of revenue was 76.6%, an increase of 3.1 percentage points. The increase in gross margin percent was primarily driven by sales of COVID-19 antibodies in Q1 2022, partially offset by lower realized prices.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q1 2023, research and development expenses increased 23% to $1.99 billion, or 29% of revenue, primarily driven by higher development expenses for late-stage assets.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Marketing, selling and administrative expenses increased 12% to $1.75 billion in Q1 2023, primarily driven by costs associated with launches of new products and indications.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;4</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q1 2023, the company recognized acquired in-process research and development (IPR&#38;D) charges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">of $105.0 million. In Q1 2022, the company recognized acquired IPR&#38;D charges of $165.6 million, primarily related to a purchase of a Priority Review Voucher.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Other income (expense) was income of $35.7 million in Q1 2023 compared with expense of $350.7&#160;million in Q1 2022. The increase in other income (expense) was primarily driven by net losses on investments in equity securities in Q1 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The effective tax rate was 12.1% in Q1 2023 compared with 7.3% in Q1 2022. The effective tax rate in Q1 2023 reflects the tax impact of the new Puerto Rico tax regime, partially offset by a net discrete tax benefit. The effective tax rate in Q1 2022 reflected the favorable tax impact of net investment losses on equity securities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q1 2023, net income and earnings per share (EPS) were $1.34 billion and $1.49, respectively, compared with $1.90&#160;billion and $2.10 in Q1 2022. EPS in Q1 2023 was </font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">inclusive of </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">$0.10</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> of acquired IPR&#38;D, compared with </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">$0.15</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> in </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Q1</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">2022</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">. </font></div><div><font><br></font></div><div id="icfb02474ee2542719995681d825190a1_10"></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">First-Quarter Non-GAAP Measures</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">On a non-GAAP basis, Q1 2023 gross margin decreased 8% to $5.46 billion. Gross margin as a percent of revenue was 78.4%, an increase of 2.3 percentage points. The increase in gross margin percent was primarily driven by sales of COVID-19 antibodies in Q1 2022, partially offset by lower realized prices.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The effective tax rate on a non-GAAP basis was 12.8% in Q1 2023 compared with 10.3% in Q1 2022. The effective tax rate for Q1 2023 reflects the tax impact of the new Puerto Rico tax regime, partially offset by a net discrete tax benefit.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;5</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">On a non-GAAP basis, Q1 2023 net income and EPS were $1.46 billion and $1.62, respectively, compared with $2.37 billion and $2.62 in Q1 2022. Non-GAAP EPS in Q1 2023 was </font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">inclusive of </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">$0.10</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> of acquired IPR&#38;D, compared with </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">$0.15</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> in </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Q1</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">2022</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For further detail on non-GAAP measures, see the reconciliation below as well as the &#34;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)&#34; table later in this press release.</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.275%"><tr><td style="width:1.0%"></td><td style="width:47.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">First Quarter</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">% Change</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (reported)</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">1.49</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2.10</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">(29)%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Amortization of intangible assets</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Net losses on investments in equity securities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.02&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.34&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Earnings per share (non-GAAP)</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1.62&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2.62&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(38)%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">Numbers may not add due to rounding.</font></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Acquired IPR&#38;D</font></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.10&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.15&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(33)%</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;6</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="icfb02474ee2542719995681d825190a1_22"></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Selected Revenue Highlights</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.326%"><tr><td style="width:1.0%"></td><td style="width:35.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.103%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:18pt"><td colspan="6" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">(Dollars in millions)</font></div></td><td colspan="15" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">First Quarter</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Selected Products</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">% Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Trulicity</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,977.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,741.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">14%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Verzenio</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">750.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">469.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">60%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">577.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">419.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">38%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Mounjaro</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">568.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Taltz</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">527.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">488.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">8%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">460.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">618.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(25)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Cyramza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">236.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">230.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;(c)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">228.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">255.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(10)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Emgality</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">154.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">149.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Tyvyt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">61.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">85.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(29)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Alimta</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">58.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">343.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(83)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Retevmo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">51.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">41.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">23%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">COVID-19 antibodies</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(d)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,469.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(100)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Total Revenue</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">6,960.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">7,810.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(11)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="18" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Jardiance includes Glyxambi</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">, Synjardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> and Trijardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> XR</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Humalog includes Insulin Lispro</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Olumiant includes sales</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab, and were made pursuant to EUAs or similar regulatory authorizations </font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM &#8211; not meaningful</font></div></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;7</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Trulicity</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q1 2023, worldwide Trulicity revenue was $1.98 billion, an increase of 14% compared with Q1 2022. U.S. revenue increased 18% to $1.55 billion, driven by increased demand and, to a lesser extent, wholesaler buying patterns, partially offset by lower realized prices driven by higher contracted rebates as well as unfavorable segment mix. Lilly experienced intermittent delays in fulfilling certain U.S. Trulicity orders in Q4 2022. These delays persisted through Q1 2023, but at a reduced level. Revenue outside the U.S. was $429.7 million, an increase of 1%, driven by increased volume, largely offset by the unfavorable impact of foreign exchange rates and lower realized prices. Actions to manage strong demand across the company's incretin portfolio, including measures to minimize existing patient impact in international markets, also affected volume.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Verzenio</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q1 2023, worldwide Verzenio revenue increased 60% compared with Q1 2022 to $750.9&#160;million. U.S. revenue was $461.1 million, an increase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">of 53%, driven by increased demand, partially offset by customer buying patterns. Revenue outside the U.S. was $289.8 million, an increase of 73%, driven by increased demand, partially offset by the unfavorable impact of foreign exchange rates and lower realized prices.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Jardiance</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company's worldwide Jardiance revenue for Q1 2023 was $577.5 million, an increase of 38% compared with Q1 2022. U.S. revenue increased 43% to $329.4 million, primarily driven by increased demand. Revenue outside the U.S. was $248.1 million, an increase of 31%, primarily driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Jardiance is part of the company's alliance with Boehringer Ingelheim. Lilly reports as revenue royalties received on net sales of Jardiance.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;8</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Mounjaro</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q1 2023, worldwide Mounjaro revenue was $568.5 million. U.S. revenue was $536.4 million. Mounjaro launched in the U.S. for the treatment of type 2 diabetes in June 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Taltz</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q1 2023, worldwide Taltz revenue increased 8% compared with Q1 2022 to $527.0&#160;million. U.S. revenue increased 2% to $312.2&#160;million, driven by increased demand, largely offset by lower realized prices. Revenue outside the U.S. increased 19%</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">to $214.8 million, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Humalog</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q1 2023, worldwide Humalog revenue decreased 25% compared with Q1 2022 to $460.9 million. U.S. revenue decreased 26% to $271.6 million, primarily driven by lower realized prices due to unfavorable segment mix. Revenue outside the U.S. decreased 24% to $189.3 million, primarily driven by lower realized prices due to the impact of VBP in China.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Olumiant</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q1 2023, worldwide Olumiant revenue decreased 10% compared with Q1 2022 to $228.9 million. U.S. revenue decreased 41% to $42.3 million, driven by a decline in utilization for COVID-19 treatment, partially offset by increased utilization for the treatment of alopecia areata. Revenue outside the U.S. was $186.5 million, an increase of 1%, driven by increased volume, largely offset by a decline in utilization for COVID-19 treatment and the unfavorable impact of foreign exchange rates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Emgality</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q1 2023, Emgality generated worldwide revenue of $154.3 million, an increase of 3% compared with Q1 2022. U.S. revenue remained relatively flat as increased demand was offset by lower realized </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;9</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">prices. Revenue outside the U.S. was $45.6 million, an increase of 11%, primarily driven by increased volume. </font></div><div><font><br></font></div><div id="icfb02474ee2542719995681d825190a1_28"></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">2023 Financial Guidance</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%">The company has updated certain elements of its 2023 financial guidance on both a reported and non-GAAP basis. Since announcing financial guidance in December 2022, the U.S. dollar has weakened against most major currencies and full-year guidance has been updated based on recent spot rates. Our guidance does not include the potential impacts of the pending business development transactions associated with the sales of the company's rights to both the olanzapine portfolio and Baqsimi. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%">Revenue guidance has been increased by $900 million to the range of $31.2 to $31.7 billion, driven by approximately $650 million associated with updates to foreign exchange rate assumptions, with the remainder attributable to underlying business performance. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%">Gross margin as a percent of revenue guidance remains unchanged on both a reported and non-GAAP basis at approximately 77% and 79%, respectively.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%">Marketing, selling and administrative expenses were increased by $100 million to reflect updated foreign exchange rate assumptions and are now expected to be in the range of $7.0 to $7.2 billion.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%">Research and development expenses were increased by $100 million driven by updated foreign exchange rate assumptions and progress within the late-stage portfolio, and are now expected to be in the range of $8.3 to $8.5 billion.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%">Acquired IPR&#38;D of $105 million in Q1 2023 has also been incorporated into guidance. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%">Other income (expense) guidance remains unchanged at a range of ($200) to ($100) million of expense on both a reported and non-GAAP basis.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;10</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%">Based on these changes, EPS guidance has been increased to the range of $8.18 to $8.38 on a reported basis and $8.65 to $8.85 on a non-GAAP basis. The company's 2023 financial guidance reflects adjustments shown in the reconciliation table below.  </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.685%"><tr><td style="width:1.0%"></td><td style="width:75.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.526%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2023<br>Expectations</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (reported)</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$8.18 to $8.38</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.45</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Net losses on investments in equity securities</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.02</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (non-GAAP)</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$8.65 to $8.85</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:140%">Numbers may not add due to rounding</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The following table summarizes the company's updated 2023 financial guidance&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:44.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2023 Guidance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:700;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(1)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prior</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Updated</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$30.3 to $30.8 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$31.2 to $31.7 billion</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Gross Margin % of Revenue (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 77%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Gross Margin % of Revenue (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 79%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Marketing, Selling &#38; Administrative</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$6.9 to $7.1 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$7.0 to $7.2 billion</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Research &#38; Development</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$8.2 to $8.4 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$8.3 to $8.5 billion</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Acquired IPR&#38;D</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">n&#47;a</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$105 million</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(2)</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Other Income&#47;(Expense)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$(200) to $(100) million</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Tax Rate</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 13%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Earnings per Share (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$7.90 to $8.10</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$8.18 to $8.38</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Earnings per Share (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$8.35 to $8.55</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$8.65 to $8.85</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP guidance reflects adjustments presented in the earnings per share reconciliation table above.</font></div></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(2) </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Guidance does not include acquired IPR&#38;D either incurred, or that may potentially be incurred, after Q1 2023.</font></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;11</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="margin-top:5pt"><font><br></font></div><div style="margin-top:5pt"><font><br></font></div><div id="icfb02474ee2542719995681d825190a1_31"></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:180%">Webcast of Conference Call</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">As previously announced, investors and the general public can access a live webcast of the Q1 2023 financial results conference call through a link on Lilly's website at investor.lilly.com&#47;webcasts-and-presentations. The conference call will begin at 10 a.m. Eastern time today and will be available for replay via the website.</font></div><div><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:180%">Non-GAAP Financial Measures</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Certain financial information for 2023 and 2022 is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the periods. Non-GAAP measures reflect adjustments for the items described in the reconciliation tables later in the release. Related materials provide certain GAAP and non-GAAP figures excluding the impact of foreign exchange rates. Lilly recalculates current period figures on a constant currency basis by keeping constant the exchange rates from the base period. The company's 2023 financial guidance is provided on both a reported and a non-GAAP basis. The non-GAAP measures are presented to provide additional insights into the underlying trends in the company's business.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:180%">About Lilly</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47</font><font style="color:#4472c4;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;12</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">healthier world, we're motivated by one thing&#58; making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Lilly.com and Lilly.com&#47;newsroom.</font><font style="color:#1f497d;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">F-LLY</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Statement Regarding Forward-Looking Statements</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains management's current intentions and expectations for the future, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words &#34;estimate&#34;, &#34;project&#34;, &#34;intend&#34;, &#34;expect&#34;, &#34;believe&#34;, &#34;target&#34;, &#34;anticipate&#34; and similar expressions are intended to identify forward-looking statements. Actual results may differ materially due to various factors. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated, including the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals&#59; the impact and outcome of acquisitions and business development transactions and related costs&#59; the expiration of intellectual property protection for certain of the company's products and competition from generic and&#47;or biosimilar products&#59; the company's ability to protect and enforce patents and other intellectual property&#59; changes in patent law or regulations related to data package exclusivity&#59; competitive developments affecting current products and the company's pipeline&#59; market uptake of recently launched products&#59; information technology system inadequacies, breaches, or operating failures&#59; unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in the company's information technology systems, networks, and facilities, or those of third parties with whom the company shares its data&#59; the impact of global macroeconomic conditions, trade disruptions, disputes, unrest, war, regional dependencies, or other costs, uncertainties and risks related to engaging in business globally&#59; unexpected safety or efficacy concerns associated with the company's products&#59; litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as the company is largely self-insured&#59; issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, or regulatory actions related to our facilities&#59; dependence on certain products for a significant percentage of our total revenue&#59; reliance on third-party relationships and outsourcing arrangements&#59; the impact of public health outbreaks, epidemics, or pandemics, such as the COVID-19 pandemic&#59; regulatory changes or other developments&#59; regulatory actions regarding operations and products&#59; continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals&#59; devaluations in foreign currency exchange rates or changes in interest rates and inflation&#59; changes in tax law, tax rates, or events that differ from the company's assumptions related to tax positions&#59; asset impairments and restructuring charges&#59; changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC)&#59; regulatory compliance problems or government investigations&#59; and actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations. For additional information about the factors that could cause actual results or events to differ materially from forward-looking statements, please see the company's latest Form 10-K and subsequent Forms 8-K and 10-Q filed with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. Except as is required by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;#</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;13</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Alimta</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (pemetrexed disodium, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Baqsimi</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (glucagon, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Cyramza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (ramucirumab, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Emgality</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (galcanezumab-gnlm, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Glyxambi</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (empagliflozin&#47;linagliptin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin lispro injection of recombinant DNA origin, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(empagliflozin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Jaypirca</font><font style="color:#000000;font-family:'Garamond',serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (pirtobrutinib, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Mounjaro</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (tirzepatide injection, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (baricitinib, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Retevmo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (selpercatinib, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Synjardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (empagliflozin&#47;metformin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Taltz</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(ixekizumab, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Trijardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> XR (empagliflozin&#47;linagliptin&#47;metformin hydrochloride extended release tablets, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Trulicity</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(dulaglutide, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Tyvyt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (sintilimab injection, Innovent)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Verzenio</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (abemaciclib, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Zyprexa</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(olanzapine, Lilly)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Third-party trademarks used herein are trademarks of their respective owners.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;14</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="icfb02474ee2542719995681d825190a1_34"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Operating Results (Unaudited) &#8211; REPORTED</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:48.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.610%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">% Chg.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,960.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7,810.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(11)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,626.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2,072.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(21)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,985.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,610.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">23%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling and administrative</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,749.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,557.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">12%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&#38;D</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">105.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">165.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(37)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,494.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2,404.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(38)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net interest income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(68.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(77.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">104.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(272.8)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(350.7)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,529.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2,053.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(26)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">184.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">150.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">23%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,344.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,902.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(29)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.49&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2.10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(29)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid per share</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">.98&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">15%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding (thousands) - diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">903,283&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">906,350&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">NM &#8211; not meaningful</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;15</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="icfb02474ee2542719995681d825190a1_403"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.018%"><tr><td style="width:1.0%"></td><td style="width:57.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.167%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td></tr><tr style="height:14pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">Gross Margin - As Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">5,333.3</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">5,737.9</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Increase for excluded items&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets (Cost of sales)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">125.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">204.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Gross Margin - Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5,459.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5,942.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">Gross Margin as a percent of revenue - As Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">76.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">73.5</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Gross Margin as a percent of revenue - Non-GAAP</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">78.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">76.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Non-GAAP gross margin as a percent of revenue reflects the gross margin effects of the adjustments presented above.</font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="margin-bottom:3pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.018%"><tr><td style="width:1.0%"></td><td style="width:57.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.167%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">Net Income - As Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,344.9</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,902.9</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) for excluded items&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets (Cost of sales)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">125.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">204.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net losses on investments in equity securities (Other income&#47;expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">388.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Corresponding tax effects (Income taxes)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(29.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(123.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net Income - Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,463.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2,372.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">Effective tax rate - As Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">12.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">7.3</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate - Non-GAAP</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share - As Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1.49</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">2.10</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.62&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2.62&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Non-GAAP tax rate reflects the tax effects of the adjustments presented above.</font></div><div style="margin-bottom:3pt;padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;16</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lly-20230427.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:0648555f-848d-4bf3-b068-d9d93f375df5,g:e4b507f7-8b41-4fa3-9cf2-cf8775bee485-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20230427" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lilly.com/20230427">
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20230427_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20230427_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20230427_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lilly.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lly_A1.700Notesdue2049Member" abstract="true" name="A1.700Notesdue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A718NotesDueJune12025Member" abstract="true" name="A718NotesDueJune12025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1.625NotesDueJune22026Member" abstract="true" name="A1.625NotesDueJune22026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A2.125NotesDueJune32030Member" abstract="true" name="A2.125NotesDueJune32030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A500NotesDue2033Member" abstract="true" name="A500NotesDue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A6.77NotesDueJanuary12036Member" abstract="true" name="A6.77NotesDueJanuary12036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1375NotesDue2061Member" abstract="true" name="A1375NotesDue2061Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1125NotesDue2051Member" abstract="true" name="A1125NotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1625NotesDue2043Member" abstract="true" name="A1625NotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A625Notesdue2031Member" abstract="true" name="A625Notesdue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>lly-20230427_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:0648555f-848d-4bf3-b068-d9d93f375df5,g:e4b507f7-8b41-4fa3-9cf2-cf8775bee485-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20230427.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended" id="i0b44c038040e4f8a9a9ef9a6f338dcdb_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_32b0fd95-b847-4168-ae26-5ec10746e3fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_DocumentType_32b0fd95-b847-4168-ae26-5ec10746e3fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c8600209-d176-4fd4-8c14-a38aa2e29527" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_DocumentPeriodEndDate_c8600209-d176-4fd4-8c14-a38aa2e29527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1398e255-0982-459e-87d8-0af97c0b6ffb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1398e255-0982-459e-87d8-0af97c0b6ffb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_73495fa1-debb-4246-9381-d267ffabc49e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityFileNumber_73495fa1-debb-4246-9381-d267ffabc49e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_2de73bf6-2311-4458-87c7-89101d823551" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityTaxIdentificationNumber_2de73bf6-2311-4458-87c7-89101d823551" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_616267c7-7244-4a04-acd0-917abd408e02" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityAddressAddressLine1_616267c7-7244-4a04-acd0-917abd408e02" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_02bc38f6-157c-4b50-9f97-24ddcca71dbc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityAddressCityOrTown_02bc38f6-157c-4b50-9f97-24ddcca71dbc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_016df624-6158-4e1b-a080-6d6804e0da27" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityAddressStateOrProvince_016df624-6158-4e1b-a080-6d6804e0da27" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c21f273a-d9ff-47cd-9280-ee3d34354590" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityAddressPostalZipCode_c21f273a-d9ff-47cd-9280-ee3d34354590" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d25bc0d1-5715-463b-9a14-3e4b321cc2ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_CityAreaCode_d25bc0d1-5715-463b-9a14-3e4b321cc2ad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2883b862-f34e-4877-a514-386d4b0edd52" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_LocalPhoneNumber_2883b862-f34e-4877-a514-386d4b0edd52" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d73a7ddc-e065-451b-8004-b6821c41f240" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_WrittenCommunications_d73a7ddc-e065-451b-8004-b6821c41f240" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_5d0909ef-c581-42fd-8ebc-bd0e8102945a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_SolicitingMaterial_5d0909ef-c581-42fd-8ebc-bd0e8102945a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_c6caa44c-2237-45b6-8d4c-24fbadba64e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_PreCommencementTenderOffer_c6caa44c-2237-45b6-8d4c-24fbadba64e1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_7aaa4b16-8593-4b89-a137-2c0ce9000989" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_7aaa4b16-8593-4b89-a137-2c0ce9000989" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b3620dea-a9c0-4a29-92c4-598baa58fcfc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityEmergingGrowthCompany_b3620dea-a9c0-4a29-92c4-598baa58fcfc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f1fece61-3673-4f31-96cf-2e9670ce273a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_Security12bTitle_f1fece61-3673-4f31-96cf-2e9670ce273a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fe620d07-f0c7-4e6e-ae1d-a413510bced7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_TradingSymbol_fe620d07-f0c7-4e6e-ae1d-a413510bced7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_47a1a6a4-03c0-406c-b440-1e73e8bf9240" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_SecurityExchangeName_47a1a6a4-03c0-406c-b440-1e73e8bf9240" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ee4255c9-07f3-4c5f-aa52-d20f288ed265" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityRegistrantName_ee4255c9-07f3-4c5f-aa52-d20f288ed265" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f4c8f0c6-a99d-41de-bb2f-b805cc3dbfa0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityCentralIndexKey_f4c8f0c6-a99d-41de-bb2f-b805cc3dbfa0" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e25cfc78-7ec3-424e-8243-7e6e0b20572a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_AmendmentFlag_e25cfc78-7ec3-424e-8243-7e6e0b20572a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_37e7bb4d-75a9-496b-ab78-90c3cc78506f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_DocumentInformationTable_37e7bb4d-75a9-496b-ab78-90c3cc78506f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_42abcd3b-c4b1-4858-b982-4713c1b25694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_37e7bb4d-75a9-496b-ab78-90c3cc78506f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_42abcd3b-c4b1-4858-b982-4713c1b25694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_42abcd3b-c4b1-4858-b982-4713c1b25694_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_42abcd3b-c4b1-4858-b982-4713c1b25694" xlink:to="loc_us-gaap_ClassOfStockDomain_42abcd3b-c4b1-4858-b982-4713c1b25694_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_42abcd3b-c4b1-4858-b982-4713c1b25694" xlink:to="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_a2568985-489c-4989-bc07-c307baba51bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_us-gaap_CommonClassAMember_a2568985-489c-4989-bc07-c307baba51bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_9d955668-2712-4ed8-94fd-1d69125d116e" xlink:href="lly-20230427.xsd#lly_A718NotesDueJune12025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A718NotesDueJune12025Member_9d955668-2712-4ed8-94fd-1d69125d116e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_d693619e-bc77-4ffb-a417-6e0093b70b74" xlink:href="lly-20230427.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A1.625NotesDueJune22026Member_d693619e-bc77-4ffb-a417-6e0093b70b74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_921f8038-32a1-4f64-b1be-25fe69d5d138" xlink:href="lly-20230427.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A2.125NotesDueJune32030Member_921f8038-32a1-4f64-b1be-25fe69d5d138" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_9c3a78a7-d060-4185-bcf4-961d0d78333f" xlink:href="lly-20230427.xsd#lly_A625Notesdue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A625Notesdue2031Member_9c3a78a7-d060-4185-bcf4-961d0d78333f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_bf55dc2f-d5f5-4356-8f90-bac32375b59b" xlink:href="lly-20230427.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_bf55dc2f-d5f5-4356-8f90-bac32375b59b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_1f75f37f-b422-408b-86b7-abe00a2c126c" xlink:href="lly-20230427.xsd#lly_A1.700Notesdue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A1.700Notesdue2049Member_1f75f37f-b422-408b-86b7-abe00a2c126c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_b80d0bb2-4fef-442d-9842-d7f365c574d8" xlink:href="lly-20230427.xsd#lly_A500NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A500NotesDue2033Member_b80d0bb2-4fef-442d-9842-d7f365c574d8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_db252775-c694-4e66-afad-02adeae53889" xlink:href="lly-20230427.xsd#lly_A1625NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A1625NotesDue2043Member_db252775-c694-4e66-afad-02adeae53889" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_29e194e6-0d92-40b3-a1ee-c59948bfdfc3" xlink:href="lly-20230427.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A1125NotesDue2051Member_29e194e6-0d92-40b3-a1ee-c59948bfdfc3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_735786a6-85c8-472b-bc3b-21fd8a26af12" xlink:href="lly-20230427.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A1375NotesDue2061Member_735786a6-85c8-472b-bc3b-21fd8a26af12" xlink:type="arc" order="10"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>lly-20230427_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:0648555f-848d-4bf3-b068-d9d93f375df5,g:e4b507f7-8b41-4fa3-9cf2-cf8775bee485-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_e009cac3-25f3-4e1b-b348-850546cf1ddf_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a00a49f7-9e4f-4c9b-b6aa-19d87cf17e2f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1125NotesDue2051Member_4b6e6fa2-15fe-4da8-b50e-00066628d4ab_terseLabel_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_label_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051 [Member]</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_documentation_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member" xlink:href="lly-20230427.xsd#lly_A1125NotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1125NotesDue2051Member" xlink:to="lab_lly_A1125NotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1625NotesDue2043Member_65a16c9f-1eae-4af7-9604-faab9c7e2fed_terseLabel_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_label_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043 [Member]</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_documentation_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member" xlink:href="lly-20230427.xsd#lly_A1625NotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1625NotesDue2043Member" xlink:to="lab_lly_A1625NotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_a7f1215b-136d-49ee-97c6-2c82eafabb37_terseLabel_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2026</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_label_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_documentation_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member" xlink:href="lly-20230427.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.625NotesDueJune22026Member" xlink:to="lab_lly_A1.625NotesDueJune22026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d386e3de-6102-40cf-891d-adb2e1229fc9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_128da322-e7e1-4c3e-9f89-c55a47489b5b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_94460090-7c18-480c-95b4-a39e465e89d8_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.700Notesdue2049Member_4982d196-ae38-4c4d-96ea-7d8a00875632_terseLabel_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_label_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_documentation_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member" xlink:href="lly-20230427.xsd#lly_A1.700Notesdue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.700Notesdue2049Member" xlink:to="lab_lly_A1.700Notesdue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e8ca8a1c-8b4d-4b00-95ca-b5135ffcc55c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1375NotesDue2061Member_79ced5c2-213b-40db-aebc-ba82ab361cb9_terseLabel_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_label_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061 [Member]</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_documentation_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member" xlink:href="lly-20230427.xsd#lly_A1375NotesDue2061Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1375NotesDue2061Member" xlink:to="lab_lly_A1375NotesDue2061Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8db9dbf9-af24-4a2b-8a44-552d62de62fd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_5692534e-e248-4a9b-96ed-d6a773ac673b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_47c3a104-5203-4c01-8d60-8c65430a2e55_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_9547be9e-9a4c-4872-8d3d-ff598593c0c2_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_21ce0159-8eb4-4e4a-8786-8622bd415862_terseLabel_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77% Notes due 2036</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_label_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_documentation_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member" xlink:href="lly-20230427.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A6.77NotesDueJanuary12036Member" xlink:to="lab_lly_A6.77NotesDueJanuary12036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A718NotesDueJune12025Member_4515dcff-d1ca-4dc1-99c4-a1a464d3c850_terseLabel_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes due 2025</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_label_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_documentation_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member" xlink:href="lly-20230427.xsd#lly_A718NotesDueJune12025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A718NotesDueJune12025Member" xlink:to="lab_lly_A718NotesDueJune12025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_465b11de-ae1f-4935-8e9a-cd28e277ca84_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_1f70b167-714c-4547-86ba-a00d7f821baf_terseLabel_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes due 2030</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_label_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_documentation_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member" xlink:href="lly-20230427.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2.125NotesDueJune32030Member" xlink:to="lab_lly_A2.125NotesDueJune32030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c3737dd3-3ce8-45ef-b51c-9709513bafda_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_977a972b-abe4-49f6-9c59-74905cdf9c21_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_04551154-5ec7-4508-9d62-2c79e5d6f141_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4e77dccb-1bff-4ded-8c69-91056fa683f1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A500NotesDue2033Member_8775ecae-1af8-4975-8fa2-1bde79db8557_terseLabel_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_label_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.500% Notes due 2033 [Member]</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_documentation_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member" xlink:href="lly-20230427.xsd#lly_A500NotesDue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A500NotesDue2033Member" xlink:to="lab_lly_A500NotesDue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_dc6ca145-5630-4f3e-b139-dc36a9f5982e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_c917227e-e192-418d-8a6b-394c551a5c9f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b04c769b-5ecc-4dbe-87a8-d8f126434cab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_0739f27e-272d-411f-83a6-135342556863_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_88d01300-36db-4917-9376-00cd6dc123ca_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_80dc4eae-04bd-4e1a-a9df-10d6e99ae42e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock (no par value)</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_a5729fa8-1754-4591-b557-852b53b56289_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_4e21fbe7-8a27-4332-9117-363b4e1419a4_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625Notesdue2031Member_8cc6f205-2cd3-433a-ba6c-17b6813bb55b_terseLabel_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.625% Notes due 2031</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_label_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_documentation_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member" xlink:href="lly-20230427.xsd#lly_A625Notesdue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625Notesdue2031Member" xlink:to="lab_lly_A625Notesdue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_08251eeb-e228-4083-a112-9852c1085f00_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_eb96f134-2e97-4a38-be3d-5af0cac01b37_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_df5239b5-2a3c-4946-aa6c-5d1609db9e02_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1f25691e-20ea-4aa2-9f58-694e7dbb253e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_2acf8d27-bd2a-4d61-afbc-8c2ae9ffb740_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>lly-20230427_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:0648555f-848d-4bf3-b068-d9d93f375df5,g:e4b507f7-8b41-4fa3-9cf2-cf8775bee485-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20230427.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7feeba34-dd2e-484c-9827-d898945b4734" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_37e7bb4d-75a9-496b-ab78-90c3cc78506f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7feeba34-dd2e-484c-9827-d898945b4734" xlink:to="loc_dei_DocumentInformationTable_37e7bb4d-75a9-496b-ab78-90c3cc78506f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_42abcd3b-c4b1-4858-b982-4713c1b25694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_37e7bb4d-75a9-496b-ab78-90c3cc78506f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_42abcd3b-c4b1-4858-b982-4713c1b25694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_42abcd3b-c4b1-4858-b982-4713c1b25694" xlink:to="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_a2568985-489c-4989-bc07-c307baba51bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_us-gaap_CommonClassAMember_a2568985-489c-4989-bc07-c307baba51bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_9d955668-2712-4ed8-94fd-1d69125d116e" xlink:href="lly-20230427.xsd#lly_A718NotesDueJune12025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A718NotesDueJune12025Member_9d955668-2712-4ed8-94fd-1d69125d116e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_d693619e-bc77-4ffb-a417-6e0093b70b74" xlink:href="lly-20230427.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A1.625NotesDueJune22026Member_d693619e-bc77-4ffb-a417-6e0093b70b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_921f8038-32a1-4f64-b1be-25fe69d5d138" xlink:href="lly-20230427.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A2.125NotesDueJune32030Member_921f8038-32a1-4f64-b1be-25fe69d5d138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_9c3a78a7-d060-4185-bcf4-961d0d78333f" xlink:href="lly-20230427.xsd#lly_A625Notesdue2031Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A625Notesdue2031Member_9c3a78a7-d060-4185-bcf4-961d0d78333f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_bf55dc2f-d5f5-4356-8f90-bac32375b59b" xlink:href="lly-20230427.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_bf55dc2f-d5f5-4356-8f90-bac32375b59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_1f75f37f-b422-408b-86b7-abe00a2c126c" xlink:href="lly-20230427.xsd#lly_A1.700Notesdue2049Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A1.700Notesdue2049Member_1f75f37f-b422-408b-86b7-abe00a2c126c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_b80d0bb2-4fef-442d-9842-d7f365c574d8" xlink:href="lly-20230427.xsd#lly_A500NotesDue2033Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A500NotesDue2033Member_b80d0bb2-4fef-442d-9842-d7f365c574d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_db252775-c694-4e66-afad-02adeae53889" xlink:href="lly-20230427.xsd#lly_A1625NotesDue2043Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A1625NotesDue2043Member_db252775-c694-4e66-afad-02adeae53889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_29e194e6-0d92-40b3-a1ee-c59948bfdfc3" xlink:href="lly-20230427.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A1125NotesDue2051Member_29e194e6-0d92-40b3-a1ee-c59948bfdfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_735786a6-85c8-472b-bc3b-21fd8a26af12" xlink:href="lly-20230427.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a3265cf5-f5aa-4291-9b70-e9199570739c" xlink:to="loc_lly_A1375NotesDue2061Member_735786a6-85c8-472b-bc3b-21fd8a26af12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_37e7bb4d-75a9-496b-ab78-90c3cc78506f" xlink:to="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_32b0fd95-b847-4168-ae26-5ec10746e3fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_DocumentType_32b0fd95-b847-4168-ae26-5ec10746e3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c8600209-d176-4fd4-8c14-a38aa2e29527" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_DocumentPeriodEndDate_c8600209-d176-4fd4-8c14-a38aa2e29527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1398e255-0982-459e-87d8-0af97c0b6ffb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1398e255-0982-459e-87d8-0af97c0b6ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_73495fa1-debb-4246-9381-d267ffabc49e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityFileNumber_73495fa1-debb-4246-9381-d267ffabc49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_2de73bf6-2311-4458-87c7-89101d823551" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityTaxIdentificationNumber_2de73bf6-2311-4458-87c7-89101d823551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_616267c7-7244-4a04-acd0-917abd408e02" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityAddressAddressLine1_616267c7-7244-4a04-acd0-917abd408e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_02bc38f6-157c-4b50-9f97-24ddcca71dbc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityAddressCityOrTown_02bc38f6-157c-4b50-9f97-24ddcca71dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_016df624-6158-4e1b-a080-6d6804e0da27" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityAddressStateOrProvince_016df624-6158-4e1b-a080-6d6804e0da27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c21f273a-d9ff-47cd-9280-ee3d34354590" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityAddressPostalZipCode_c21f273a-d9ff-47cd-9280-ee3d34354590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d25bc0d1-5715-463b-9a14-3e4b321cc2ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_CityAreaCode_d25bc0d1-5715-463b-9a14-3e4b321cc2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2883b862-f34e-4877-a514-386d4b0edd52" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_LocalPhoneNumber_2883b862-f34e-4877-a514-386d4b0edd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d73a7ddc-e065-451b-8004-b6821c41f240" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_WrittenCommunications_d73a7ddc-e065-451b-8004-b6821c41f240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_5d0909ef-c581-42fd-8ebc-bd0e8102945a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_SolicitingMaterial_5d0909ef-c581-42fd-8ebc-bd0e8102945a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_c6caa44c-2237-45b6-8d4c-24fbadba64e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_PreCommencementTenderOffer_c6caa44c-2237-45b6-8d4c-24fbadba64e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_7aaa4b16-8593-4b89-a137-2c0ce9000989" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_7aaa4b16-8593-4b89-a137-2c0ce9000989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b3620dea-a9c0-4a29-92c4-598baa58fcfc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityEmergingGrowthCompany_b3620dea-a9c0-4a29-92c4-598baa58fcfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f1fece61-3673-4f31-96cf-2e9670ce273a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_Security12bTitle_f1fece61-3673-4f31-96cf-2e9670ce273a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fe620d07-f0c7-4e6e-ae1d-a413510bced7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_TradingSymbol_fe620d07-f0c7-4e6e-ae1d-a413510bced7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_47a1a6a4-03c0-406c-b440-1e73e8bf9240" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_SecurityExchangeName_47a1a6a4-03c0-406c-b440-1e73e8bf9240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ee4255c9-07f3-4c5f-aa52-d20f288ed265" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityRegistrantName_ee4255c9-07f3-4c5f-aa52-d20f288ed265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f4c8f0c6-a99d-41de-bb2f-b805cc3dbfa0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_EntityCentralIndexKey_f4c8f0c6-a99d-41de-bb2f-b805cc3dbfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e25cfc78-7ec3-424e-8243-7e6e0b20572a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4923ae78-eeec-497c-8497-a3b616d245cc" xlink:to="loc_dei_AmendmentFlag_e25cfc78-7ec3-424e-8243-7e6e0b20572a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logoa31.jpg
<TEXT>
begin 644 logoa31.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P *N\.7.;BYMSQXINDX\WC_ )=XS_JTZ.?GY_=^7]'?\' /_!4K_A#;&\^
M_@&Z_P")CJ5MM\8:C ?^/6!QC^ST[^9(G^L[>6XCY\Q]GYA_L7?LD^*OVW?C
MQI/@'PNO^D7A\^^U!A_H^DVJ$"6XD_Z9Q[_;>\B)U>OSSBC.IUZG]FX36[M*
MV[?\OIW\_0_L;P(\,\-EF"?&_$=H*,7*DI:*$4M:LK]7M3\O>5W*-O0O^"8G
M_!-[Q!_P4/\ C2FGPM=:3X*T-A-X@U=DXM8NUM#G@S2=A_!]\]@?Z*/@G\$O
M#?[.7PNTKP;X/TRVT'P_H<'DVMO"!G.3F1C_ !R.Q+N[<NQ).2:Y[]DG]EGP
MK^QS\$=*\ ^$+(6NE::-TTTS!IM1F<J9+F9_XI'/X#"H,(B8_/S_ (*O_P#!
M>33?A_!J'PY^"&HV^J:Y(#!JGBZ$K-::;V\JS(XEG[F;[D?\'F.?W?JX#"X3
M(<+[7$OWWOU;?:)\#Q5G_$'BOQ LNR:#6&IOW4[J,8[>UJO92:V3O;X8IRO?
M:_X+A?\ !72U^!N@ZK\&_AKJ0D\<ZE#Y.OZK;2\>'X'^];Q..EVZ\?\ 3-.F
M'*%/Q^_9Q_9W\5?M8_&+0_!/@[3_ +9K6L3_ "G!\FVB_P"6EQ,_\$:?YYZK
M\%O@GXU_:O\ C+9^&O">FWGBKQ-K5QYV02<\_O+B:1_N1\Y=WK^A+_@F!_P3
M%\-_\$[OA7Y*_9]<\>ZY O\ ;^N[, ]"+> $96!#]"Y&]L?(D?S='#XK/\9[
M:KI2C]R79=V^K/VS-<WR/PAX<_LO -5,=55^G-*5K>TG9Z4XZ\L;ZVLM7*1Z
M5^Q=^R-X<_8C_9TT+P!X=7=;Z8#/?WKH(Y=2O'VF6YDZ\N> ,_(B(@X05[91
M17Z?2IQIP5."LDK)'\*X['8C&XFIC,7-SJ5&Y2;W;>K?W_U8*I75Y!IU@UQ,
MWD0P<DGH!7Q=_P %(_\ @LAX"_8*L[C0M/:V\:?$IE4#0;:?;%IP?!$E[)SY
M?R?.(_\ 6/E/N(_F#\4?VI_^"@/Q>_;P\2;?&'B35=5LKJX']G^'M/5[?3;:
M3?\ NXX[>/[[^CR>8_3YZ^>S;B?#8*7LX^_/LNGJ^C/V3P\\"<]XGI+'5FL-
MAFKJ<TVY+O&%TVO-M+LVC^B.3]OWX&6VN_V:WQC^%XU#?Y/V<^*;'=YO_//_
M %GWO;K7KMI<0:C9?:(2+B&XY!'0BOY'_&?@C6OAMXENM%\0Z7JVAZQ9X^TV
M%[;/9W=L70.F^-_G3Y'1^:_;[_@V<^(WB#QC^Q]XJT75KJZO-,\,^(!#I#3G
M_CVCDMXY'MT_V _S_P#;<UQ9'Q//&8GZM5I\KMTONNC3/I/%'P(PO#60K/<O
MQCJQ3BFI*.JGHI1<79Z]-;K6ZMK^EU%%%?8G\VA1110 4444 %%%% !1110
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M[XA_MM+<>'/#ZMX#^&]T?(N=+MIQ]NUB+'6ZG_N?],8\1_.0_F8!KR?]A/\
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M!M=#\,V,M_=3J 3L3G8@_B=SA47N2.]<1^R'^P3\+OV)=!OK7X>^&_[+FU3
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M5M7:2=^H_P""Q?\ P67O?VN]5O/AS\/+V[T_X8V5SMN[U6,,_BB6-NI_N6W
M*)_']]_[B>8?\$GO^"8&N?\ !0CXK"\U);K2/A?X:N -9U11M-W+_K!90_\
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M>Z/<Z9':M-:W-K]JMQ/;^>,>?$?XTKX//N+G53H8&Z766S?IU2\^I_5GA/\
M1VA@:L,UXJY95%9PHK6,7WF]I-:62O%=7)Z+K?V?O@?XA_:8^,V@>!_"=J+S
M7/$UU]FME)_=#^.21_[B1HCN_P#L)7]+'[#W[*-C^Q/^S-HGP[T_5+[61I4)
M:ZOYYY/](NI"&F>./=B&,N251#QGDNY=W_,?_@VIN_ACX+U3XC>(O$'BCP_I
MOCR18K&QM=2O([62#3R!)+)#YA&\22;1)_<\B/L]?>O[1'_!9?\ 9S_9WTZ=
MK[XB:;XJU)4^33_"[)JT\YQ@Q^9&?)0_]=)$^M>APGAL)A,+]=KS2E+N]E?;
MU?4^3^D!G7$'$6?+A;*L+4G1H.+:C!OGFXWYFTG:$4[)W26K;VM]<5_-7_P6
MP^)L_P 4?^"G7Q.N&F9K?1+J'1;4?\\5M8(XW _[:"1_^!UZQ^W%_P '!WQ.
M_:-%UH?P^A/PM\(S9A^U03^=K-W%W+S@?N<_(=D $@Y'F.*_/::?SOOUY'%/
M$%#&TUA\/=I.[?1Z;+KUZV/T+P%\'<TX:Q53.LYY8U)TW"--:RBFTVY-:)^Z
MK)<R=_B35CH[GXCZW>_#VW\*-J%U_P (WI=U-J4%D !";QT2-[EP!\\GEHB;
MWZ(FP5^D/_!+K_@@'K'Q=>T\;_&^SOM!\)9$]AX8R\&HZKU)^T_QV\' ^3_6
M/G_EGP9.:_X(/?$#]F'X=^++G4OBA)9Z3\4;6Z\_0=5\17*?V3:PXZP%L1PW
M"/\ \M)N?N>6^=XK]F-3_:S^%VC: =4NOB=\/[;3P/\ CYFU^T$!_P"![\?K
M6W#>1X6O!8K%5%+M&^UOYO\ (\CQH\5<^RNO4X>X?PDZ/,VY5N36?-J_9636
MM[.;;E=;1:3.K\)^%--\#>'K/1-$TZSTG2M+@$%I8V\*0PV\2#"(B+PJ5T=?
M%_QZ_P""Z_[./P!@GCB\8?\ ";ZI:#'V#PQ ;[.?2X.RV/\ W\K\X_VP/^#B
M_P"*_P ;Q<:3\.--M/AGH<Z^4;F&X%WK%P/:X*;(LC_GG'YB'^.OK,9Q)@,)
M&SGS/M&S_P"!^)_/?"_@KQ?G]13CAG2@]74JW@N[=G><KOM%_(^/?VW_ (T_
M\-'_ +8?Q&\:BZ-Y:Z]X@NI[.8#'^B))Y<'Y0I&/PK6^,W[:WC+XI_ GPA\+
M;5ET'X:^#=.@M[;0M.8B#4;L?O)[VXDX\Z629Y).?W<?1.=[OX?7ZW?\$'_
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MQ1VNP_N4C_@V=_GSOYK@=2FN-1>XU"\:ZNKB\N9?.N9_W@GE^^_[S^*3Y_\
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MIO\ PK6^NO"O_"-W$6HWWBZ%G6#0$!P?NX\R=_GV0_\ +3G.Q-\@B_X)Q?\
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M\[(ER,EXB4^Z2A)?97YMZ]^P!\<_"^I?V?>_!OXEI= ]!X8O)@?^N;I'L?\
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MX"?#KX?^*OVC_BMIOAO0[.\U[Q1XNU 06ZD^=-<SR.=\LC_F[N_^VY]:[/\
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MHHHK8\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140601676482304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Apr. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 27,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-06351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-0470950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lilly Corporate Center<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELI LILLY AND COMPANY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000059478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock (no par value)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (no par value)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member', window );">7 1/8% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">7 1/8% Notes due 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member', window );">1.625% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member', window );">2.125% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Notes due 2030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member', window );">0.625% Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Notes due 2031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member', window );">6.77% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.77% Notes due 2036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member', window );">1.700% Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.700% Notes due 2049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY49A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member', window );">0.500% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member', window );">1.625%&#160;Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member', window );">1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.125% Notes due 2051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member', window );">1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>lly-20230427_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lly="http://www.lilly.com/20230427"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lly-20230427.xsd" xlink:type="simple"/>
    <context id="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="ib841fae2ec0041df94d705b7c5c14954_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="ia053b0dde893464cb58e570dbaa02309_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="i714a0c27150a4568b4850965bd5f6641_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="i2acc59ac3a0c401d9b6f057b8da86a38_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="if0b01fdf8cee4e8f9817ca496a034993_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="ie516118962284c77abd784c53b345cc4_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="ic889a2b0adaf47e9b220814578c43df0_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="i500b5a8110364b38a2336189ed914378_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="i529ddd44d0494587a58bf97eea7a37e5_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="ieb727a34f7b546539b8a597247d52660_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="iaa3feeb9856e4ce6833d755e771f1f07_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF80L2ZyYWc6MzYwYmRkNTdhZmI1NGZmYThkZTc2NWI3MjQyNjRkMDgvdGFibGU6NmE1MzBhYWJiZDFjNDIyOGJhNjZkYjQ5NTEwYzcxNjYvdGFibGVyYW5nZTo2YTUzMGFhYmJkMWM0MjI4YmE2NmRiNDk1MTBjNzE2Nl8yLTEtMS0xLTI0NjI1OQ_05aeaf74-1508-4fc2-bfb0-c70be6d9ce50">0000059478</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF80L2ZyYWc6MzYwYmRkNTdhZmI1NGZmYThkZTc2NWI3MjQyNjRkMDgvdGFibGU6NmE1MzBhYWJiZDFjNDIyOGJhNjZkYjQ5NTEwYzcxNjYvdGFibGVyYW5nZTo2YTUzMGFhYmJkMWM0MjI4YmE2NmRiNDk1MTBjNzE2Nl81LTEtMS0xLTI0NjI1OQ_b69f4922-e3a5-4e5d-93ae-4c35f8de7678">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGV4dHJlZ2lvbjplZjNlMzcwZjgyNWE0MTQ2OTkyOGVjMmUyOTliYzlmNV8xMTg2_3473ab51-eac2-4d98-80f0-7c6a6e93d106">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGV4dHJlZ2lvbjplZjNlMzcwZjgyNWE0MTQ2OTkyOGVjMmUyOTliYzlmNV8xNTk_1f3870c5-141a-483e-b684-1d273264ae8c">2023-04-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGV4dHJlZ2lvbjplZjNlMzcwZjgyNWE0MTQ2OTkyOGVjMmUyOTliYzlmNV8xMTg3_ce1947d2-0ff5-43ee-90e7-6ec5d91d095a">ELI LILLY AND COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6NGJkNWY5MjkwNDRhNDg5M2I1ZjQ4OGNkZmI0YjNkMWQvdGFibGVyYW5nZTo0YmQ1ZjkyOTA0NGE0ODkzYjVmNDg4Y2RmYjRiM2QxZF8wLTAtMS0xLTI0NjI1OQ_ef7fc549-d913-49c4-ab40-8631fe5f0c8f">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6NGJkNWY5MjkwNDRhNDg5M2I1ZjQ4OGNkZmI0YjNkMWQvdGFibGVyYW5nZTo0YmQ1ZjkyOTA0NGE0ODkzYjVmNDg4Y2RmYjRiM2QxZF8wLTItMS0xLTI0NjI1OQ_27f7c0f6-4f0a-47c0-af22-2a9cc2a0fd46">001-06351</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6NGJkNWY5MjkwNDRhNDg5M2I1ZjQ4OGNkZmI0YjNkMWQvdGFibGVyYW5nZTo0YmQ1ZjkyOTA0NGE0ODkzYjVmNDg4Y2RmYjRiM2QxZF8wLTQtMS0xLTI0NjI1OQ_ce03be71-1b32-43a4-b321-f4fc61e76da6">35-0470950</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZThiOTFjNzE2NmJiNGE0YmI2ZmRlMjVhMDBjODMzMDEvdGFibGVyYW5nZTplOGI5MWM3MTY2YmI0YTRiYjZmZGUyNWEwMGM4MzMwMV8wLTAtMS0xLTI0NjI1OQ_94a1b355-cbab-4843-996f-4a1d1c16fbbf">Lilly Corporate Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZThiOTFjNzE2NmJiNGE0YmI2ZmRlMjVhMDBjODMzMDEvdGFibGVyYW5nZTplOGI5MWM3MTY2YmI0YTRiYjZmZGUyNWEwMGM4MzMwMV8xLTAtMS0xLTI0NjI1OQ_c22543e6-da87-4466-ab69-e43d8c4d1733">Indianapolis,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZThiOTFjNzE2NmJiNGE0YmI2ZmRlMjVhMDBjODMzMDEvdGFibGVyYW5nZTplOGI5MWM3MTY2YmI0YTRiYjZmZGUyNWEwMGM4MzMwMV8xLTEtMS0xLTI0NjI1OQ_8a9024dc-f2aa-44fa-a70d-fb327036027b">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZThiOTFjNzE2NmJiNGE0YmI2ZmRlMjVhMDBjODMzMDEvdGFibGVyYW5nZTplOGI5MWM3MTY2YmI0YTRiYjZmZGUyNWEwMGM4MzMwMV8xLTItMS0xLTI0NjI1OQ_8eea13da-ec4d-4e7e-93ba-3c7925a7eefc">46285</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGV4dHJlZ2lvbjplZjNlMzcwZjgyNWE0MTQ2OTkyOGVjMmUyOTliYzlmNV8xMTg4_f0eb0f41-0cbd-433e-9f10-7ad855c2052e">317</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGV4dHJlZ2lvbjplZjNlMzcwZjgyNWE0MTQ2OTkyOGVjMmUyOTliYzlmNV8xMTg5_63b5004b-3a4b-45e3-bc9b-606c7b400aef">276-2000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZTdkZjgyY2M1NzAyNGJlMDkwYzZhMjM5M2JiNmQ2MGUvdGFibGVyYW5nZTplN2RmODJjYzU3MDI0YmUwOTBjNmEyMzkzYmI2ZDYwZV8wLTAtMS0xLTI0NjI1OQ_5567bcc6-cb76-4fce-a7f0-187dc41eaec4">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6YWRiNmVkNDA2YmQ1NDA4M2E1ZWY2ZGQyNTM1M2E0ZjIvdGFibGVyYW5nZTphZGI2ZWQ0MDZiZDU0MDgzYTVlZjZkZDI1MzUzYTRmMl8wLTAtMS0xLTI0NjI1OQ_8ffdd6a7-0ca9-45ef-a91b-b8b57b06438a">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6MjBhMzM4MmI2NDYxNDFkYzgxNTcyMjFjNWQ3MzJhYzAvdGFibGVyYW5nZToyMGEzMzgyYjY0NjE0MWRjODE1NzIyMWM1ZDczMmFjMF8wLTAtMS0xLTI0NjI1OQ_02fd2e0c-984f-4f5e-bb00-a333b377bc4d">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6YWM2OTZlMTIzMWE2NGVkZmIwNzc4NzNhOGNlNTNhNGMvdGFibGVyYW5nZTphYzY5NmUxMjMxYTY0ZWRmYjA3Nzg3M2E4Y2U1M2E0Y18wLTAtMS0xLTI0NjI1OQ_ee06fdd6-3521-4776-baf7-b1279cf092ed">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ib841fae2ec0041df94d705b7c5c14954_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xLTAtMS0xLTI0NjI1OQ_c79791ea-60ee-4a52-9149-30277a8cc310">Common Stock (no par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib841fae2ec0041df94d705b7c5c14954_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xLTItMS0xLTI0NjI1OQ_ab1f3845-3dd3-4a1d-93fe-d2c04a58748d">LLY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib841fae2ec0041df94d705b7c5c14954_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xLTQtMS0xLTI0NjI1OQ_26954b00-82c7-4f36-85ca-b161aeafb69b">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ia053b0dde893464cb58e570dbaa02309_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8yLTAtMS0xLTI0NjI1OQ_19cb295b-137d-43f2-a73c-54ceaef0f582">7 1/8% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia053b0dde893464cb58e570dbaa02309_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8yLTItMS0xLTI0NjI1OQ_a7d723ab-c804-488f-83f9-5d2efafc3200">LLY25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia053b0dde893464cb58e570dbaa02309_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8yLTQtMS0xLTI0NjI1OQ_babc635f-4018-4e8e-8b95-022b2c8fd9b1">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i714a0c27150a4568b4850965bd5f6641_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8zLTAtMS0xLTI0NjI1OQ_c1c7f50c-60db-4f8a-b0fa-4c45ac50168d">1.625% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i714a0c27150a4568b4850965bd5f6641_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8zLTItMS0xLTI0NjI1OQ_fae0da6c-ae3a-499f-8dd2-dc5897a0e6d7">LLY26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i714a0c27150a4568b4850965bd5f6641_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8zLTQtMS0xLTI0NjI1OQ_f654bfd2-1d48-4e89-8f43-81c3b59d42aa">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i2acc59ac3a0c401d9b6f057b8da86a38_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl80LTAtMS0xLTI0NjI1OQ_e180bf71-a993-4e48-8529-c6393a02f4b1">2.125% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2acc59ac3a0c401d9b6f057b8da86a38_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl80LTItMS0xLTI0NjI1OQ_67b53ce6-7f3e-4a85-a51f-52561020fd74">LLY30</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2acc59ac3a0c401d9b6f057b8da86a38_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl80LTQtMS0xLTI0NjI1OQ_5226de6d-4e8a-46fe-9f79-cb4c6db1429e">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="if0b01fdf8cee4e8f9817ca496a034993_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl81LTAtMS0xLTI0NjI1OQ_c478f30f-f717-438e-8a20-5f766df70e9d">0.625% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if0b01fdf8cee4e8f9817ca496a034993_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl81LTItMS0xLTI0NjI1OQ_1f2dccc4-c393-46b1-b1de-f88f7adc2d23">LLY31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if0b01fdf8cee4e8f9817ca496a034993_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl81LTQtMS0xLTI0NjI1OQ_283434a4-d479-487b-88d1-e79afde67dfb">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ie516118962284c77abd784c53b345cc4_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl82LTAtMS0xLTI0NjI1OQ_f75a0195-1df4-4c2d-a9aa-abb02662b734">0.500% Notes due 2033</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie516118962284c77abd784c53b345cc4_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl82LTItMS0xLTI0NjI1OQ_6a199be1-0ae4-4368-9e9d-39e7565a4736">LLY33</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie516118962284c77abd784c53b345cc4_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl82LTQtMS0xLTI0NjI1OQ_3b9d2545-3576-4357-aecd-55dfcdf86bc1">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ic889a2b0adaf47e9b220814578c43df0_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl83LTAtMS0xLTI0NjI1OQ_4bb9cd58-340b-4ece-9782-c0a04ce64f58">6.77% Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic889a2b0adaf47e9b220814578c43df0_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl83LTItMS0xLTI0NjI1OQ_914fc5a8-b67b-45b0-9bbb-3c08408fbd58">LLY36</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic889a2b0adaf47e9b220814578c43df0_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl83LTQtMS0xLTI0NjI1OQ_58fe7fa2-cb5e-48f8-a163-b1c0baa73887">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i500b5a8110364b38a2336189ed914378_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl84LTAtMS0xLTI0NjI1OQ_5839ad73-7ffb-40aa-bde8-111d7d15e3ad">1.625% Notes due 2043</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i500b5a8110364b38a2336189ed914378_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl84LTItMS0xLTI0NjI1OQ_0b145456-d978-417f-a8ad-db859afd0d92">LLY43</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i500b5a8110364b38a2336189ed914378_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl84LTQtMS0xLTI0NjI1OQ_b17ffb2a-685f-4ba9-9b52-225eb480c4b2">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i529ddd44d0494587a58bf97eea7a37e5_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl85LTAtMS0xLTI0NjI1OQ_2ea5f90c-f2aa-47bb-adef-9d6c867be347">1.700% Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i529ddd44d0494587a58bf97eea7a37e5_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl85LTItMS0xLTI0NjI1OQ_da5492d2-2255-4589-a614-627fbdff8021">LLY49A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i529ddd44d0494587a58bf97eea7a37e5_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl85LTQtMS0xLTI0NjI1OQ_f6504b53-3755-4fe8-8937-0c8586586365">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ieb727a34f7b546539b8a597247d52660_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xMC0wLTEtMS0yNDYyNTk_dd0b21dc-b367-4f45-a5b8-1fa828f19aa6">1.125% Notes due 2051</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ieb727a34f7b546539b8a597247d52660_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xMC0yLTEtMS0yNDYyNTk_ecc64802-d6a6-4488-8dac-d57bea302b66">LLY51</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ieb727a34f7b546539b8a597247d52660_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xMC00LTEtMS0yNDYyNTk_14d54397-58dc-4a50-b6ff-76e38a0a52e2">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="iaa3feeb9856e4ce6833d755e771f1f07_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xMS0wLTEtMS0yNDYyNTk_9591e090-adf1-4eb6-8f8e-ecb2216fd131">1.375% Notes due 2061</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iaa3feeb9856e4ce6833d755e771f1f07_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xMS0yLTEtMS0yNDYyNTk_fad0b3ae-aa79-4981-8fbe-2894f64e2948">LLY61</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iaa3feeb9856e4ce6833d755e771f1f07_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGFibGU6ZWQxNjhmNmMzYmY2NDQyNmIxZjA1ODZhOTAwN2I5N2IvdGFibGVyYW5nZTplZDE2OGY2YzNiZjY0NDI2YjFmMDU4NmE5MDA3Yjk3Yl8xMS00LTEtMS0yNDYyNTk_00005cef-0f32-43ef-8875-646f642d6c01">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3NzJmZTVkYzY2NjRkNTdhNzU5NmM0YTQwMDk2ZjlkL3NlYzo1NzcyZmU1ZGM2NjY0ZDU3YTc1OTZjNGE0MDA5NmY5ZF8xL2ZyYWc6ZWYzZTM3MGY4MjVhNDE0Njk5MjhlYzJlMjk5YmM5ZjUvdGV4dHJlZ2lvbjplZjNlMzcwZjgyNWE0MTQ2OTkyOGVjMmUyOTliYzlmNV8xMTg1_8e216d32-98b8-4a4a-af77-4b42094ced19">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MIR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M6#B;5L !T=?N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ 6#B;5IE<G",0!@  G"<  !,
M ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !8.)M6HVV]
M[_4&   3,0  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ 6#B;5I^@&_"Q @  X@P   T
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;72YX;6Q02P4&      D "0 ^ @  D!8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>12</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>11</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lly-20230427.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lly-20230427.htm">lly-20230427.htm</File>
    <File>lly-20230427.xsd</File>
    <File>lly-20230427_def.xml</File>
    <File>lly-20230427_lab.xml</File>
    <File>lly-20230427_pre.xml</File>
    <File>q123lillysalesandearningsp.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="52">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lly-20230427.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 52
   },
   "contextCount": 12,
   "dts": {
    "definitionLink": {
     "local": [
      "lly-20230427_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lly-20230427.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lly-20230427_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lly-20230427_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lly-20230427.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 38,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 10,
   "memberStandard": 1,
   "nsprefix": "lly",
   "nsuri": "http://www.lilly.com/20230427",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230427.htm",
      "contextRef": "i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.lilly.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230427.htm",
      "contextRef": "i77366e74aa54433aaadafc54fd03dd62_D20230427-20230427",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 11,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "lly_A1.625NotesDueJune22026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due June 2, 2026 [Member]",
        "label": "1.625% Notes Due June 2, 2026 [Member]",
        "terseLabel": "1.625% Notes due 2026"
       }
      }
     },
     "localname": "A1.625NotesDueJune22026Member",
     "nsuri": "http://www.lilly.com/20230427",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.700Notesdue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.700% Notes due 2049 [Member]",
        "label": "1.700% Notes due 2049 [Member]",
        "terseLabel": "1.700% Notes due 2049"
       }
      }
     },
     "localname": "A1.700Notesdue2049Member",
     "nsuri": "http://www.lilly.com/20230427",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1125NotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.125% Notes due 2051",
        "label": "1.125% Notes due 2051 [Member]",
        "terseLabel": "1.125% Notes due 2051"
       }
      }
     },
     "localname": "A1125NotesDue2051Member",
     "nsuri": "http://www.lilly.com/20230427",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1375NotesDue2061Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% Notes due 2061",
        "label": "1.375% Notes due 2061 [Member]",
        "terseLabel": "1.375% Notes due 2061"
       }
      }
     },
     "localname": "A1375NotesDue2061Member",
     "nsuri": "http://www.lilly.com/20230427",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1625NotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625%\u00a0Notes due 2043",
        "label": "1.625%\u00a0Notes due 2043 [Member]",
        "terseLabel": "1.625%\u00a0Notes due 2043"
       }
      }
     },
     "localname": "A1625NotesDue2043Member",
     "nsuri": "http://www.lilly.com/20230427",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2.125NotesDueJune32030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.125% Notes Due June 3, 2030 [Member]",
        "label": "2.125% Notes Due June 3, 2030 [Member]",
        "terseLabel": "2.125% Notes due 2030"
       }
      }
     },
     "localname": "A2.125NotesDueJune32030Member",
     "nsuri": "http://www.lilly.com/20230427",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A500NotesDue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.500% Notes due 2033",
        "label": ".500% Notes due 2033 [Member]",
        "terseLabel": "0.500% Notes due 2033"
       }
      }
     },
     "localname": "A500NotesDue2033Member",
     "nsuri": "http://www.lilly.com/20230427",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A6.77NotesDueJanuary12036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "label": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "terseLabel": "6.77% Notes due 2036"
       }
      }
     },
     "localname": "A6.77NotesDueJanuary12036Member",
     "nsuri": "http://www.lilly.com/20230427",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625Notesdue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".625% Notes due 2031 [Member]",
        "label": ".625% Notes due 2031 [Member]",
        "terseLabel": "0.625% Notes due 2031"
       }
      }
     },
     "localname": "A625Notesdue2031Member",
     "nsuri": "http://www.lilly.com/20230427",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A718NotesDueJune12025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "label": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "terseLabel": "7 1/8% Notes due 2025"
       }
      }
     },
     "localname": "A718NotesDueJune12025Member",
     "nsuri": "http://www.lilly.com/20230427",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock (no par value)"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000059478-23-000160-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000059478-23-000160-xbrl.zip
M4$L#!!0    ( %@XFU:N[\'1Q!\  $ 7 0 0    ;&QY+3(P,C,P-#(W+FAT
M;>U];5?;/+;V]_,K_##KG-.N506]6C;MS5G<A#)T2&@AE$F^=,F61!R<A'$<
M(/SZ9\M)*)#PV@"%>M8])8EL6=*^=.U+VI+UZ?_.NJEW8K)!TN_]M40J>,G[
MO]5/_P^A?_^]N^U5^_&P:WJYMYX9E1OMG29YVSO09G#DV:S?]0[ZV5%RHA J
M[EGO'X^RY+"=>Q13=BTQ6\$^#X00%@4\T(A'EJ$(^P'2H0Z995)H*SX<KA@>
M"2RM1$'$">)6,13&EJ+8!E**R!C(Y8->$5)2:X2.?=_G6D@E1>C'7'&,0]^&
MVCVVG4/MH(:]P<I9E*7)7TOM/#]>65X^/3VMN%\J_>QPF6+,EI/>(%>]V"Q-
MKD_.\OE7)[TTZ1G7/,MYIGH#V\^Z*H?F@WPH1I@B0B]E@@8FOI(1?*\<]D]N
MS8<(A /$R"2?*_>?LJ(8) S#Y3-7P>G#M/E9OZ*TTR=!@BO;1:F& W2HU/'%
MQ58-HB+/2<*5BUU.^EK&DT;SE\>)%Y="A8YN+JM+_=DP-YF"L$LM<Y'S()F7
M+Y2!+/^[MKT7MTU7H>LF3-/1E;O2!'ZIQ/VNJR##G,J+*Z\7_"HV7'*D!N.,
M5U+5._QKR?30_MX20,PHO?JI:W+EN?N1^<\P.?EK:;W?RZ'CH,;H&&Z+Q]_^
M6LK-6;Y<&&UY];_^Z[\^Y4F>FE4H%IH6Z=/R^+=/R^.<H[X>K7[2R8DWR$>I
M^6M))X/C5(U6>OV>@><G9RON0I.-/R9:FU[Q$=+KT'FS)!X__BS?-?:OI41*
MYOM&<J4$YXPII;2RL>!68Z:U3W]4IT5!/YNII[KNT299V>A!^4;K4)M,I5L]
M;<[^949+7J(A:\V^CZ)J_V2;[IXT66VH.QLGK<VPL]/99_7S+]U6X_M1\[Q)
MZYW=HWI#M^OG^Z+>K>%FX]MIK7I$6YWT:)O5T^9YG]3/XU&KNT]:FS6XOHE;
MU7W6;,1DI]'JU#<W<*VZ!O<V1>MS@+=I:]0\B/W:>?.TV1WGW>IND?IFJ]ML
MM(]:C9C6#[98K?-MY)Y=JQZ>Z,W/2;2Y[]>[&Z1V_G>[>? E:54_=^K5K='.
MYI=VO=,Z:G:^B7ICX[1Y'I]!&2;W?(=GB5ZKT:?-QOYY;?-SN]G]<E0[J.%:
M9XLWNQNTWMU-ZM4C4FO\W:F?P_<T&&TW-O+:'C[;;FSA>F>+['S[@84RRDJ.
MB(#>SFU,460CC&*)(^/K,#8"+ZUB]S\1<AE\6KYBUJ>T\AJPOG;,_SE5AZ5U
M[[(NF6/=R \M#RE%ABF!.'@J%#)E$(^9L($VTI?!TJI5Z<#,&';Y:E?.C#69
M 68;S"$@1TXK@X(!P?1>0;,K.=#.7TN#I'N<.M8J?FMG#AF7N:9R-M"0P_+5
M+,:/__G,21$&_6%6?"L\Z<H$;6-H/ 9MTXQ,02C3;XEVWVUB,J\HD)GK.]>W
M_G6U8UR_>77ZT]7<CZ%Y^WKZ#;Q%EE=!UZRZ0B',D:/?ZVD7Q=0W7#I-F7Z?
M/F3Y2D/-;;<HX,0J0TV,,2?:AEQ++"(9BYCP4/ 7:+=)]<VAZ_WCKQH>=G:<
M)G&2UTPW@D?H!%+'DG&B&5;V<F@#=\]ZJ@:#';N7]^.CM;-DL+0ZO62]W^WV
M>T7ZVCBC3\MS\[]HNXMBO IK*BQ8A*'7!B'C/H\C$1@AL8Z4<L8+WX8U@4!6
MUB0)ZOW<#*I#\V78,P3J(]ZB227A"L=4@H=67/@P(@D$#"]$I(6%80=Y0R8E
M%9^*RT:E4"/_+1J5JC@6H8H9F)9CHL/(MUC(*- J\!4+WI!1:85<-2JCF.&W
M:%2+(TRLMD%L##>!#0,B8\5#7V'&PY"](:-.^ZD>&K F>8O6-(+XA 2A3VG
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M:T6EIVHT6%I^PA,4KOHX_^K+/_T7B[E=FMT;!\%,9O059$U>J.F10E!,@F*
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MXX8&GE;CGF5:V-%N](F/=MOHY8[F)K7>+"J]/J[S6SS5[3O7__R2MFAZ$G6
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MR*#UK]^;HFVA.JQGLT6U;/'GTX1CA,&R3X!J3#&%9<%2;/N"MIA@$@<1.6P
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M/C/^)!4WFG_A*@ZG[/XC"C_LW>'D/5Z^>;6\W?WI_D>K-Z_^"U!+ P04
M" !8.)M6_/_"8^00  #?I   %    &QL>2TR,#(S,#0R-U]L86(N>&ULU5UK
MC]LXEOV>7Z&IP0QF@+!*?$K,=C+(5'</LIM.@DX:/=C&P.!+%:-=5D%6)57_
M?BG9KE@V+9&2K=9^21R'O#SW6/?!ZTOZNW\\W"ZB+Z98S?/ERPMX&5]$9JER
M/5_>O+SXY=./(+WXQZMGS[[[$P#__N?/;Z/O<W5_:Y9E=%T841H=?9V7GZ-?
MM5G]'F5%?AO]FA>_S[\( %[5DZ[SN\=B?O.YC%",\/[_%B]B1E)*:092DFI
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M59A-=6:>>2R0M*."7)0,#F."F!DZSH17.FQ$QFV;_;#8G873#54=F8DW#79
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M&;QN"X,8>"H*CM4(-D<"'G[%9<%,(O1B,25X'B9X/LZ[PP#53N-Y1@Z6],Y
M%+@^8L)W80V F3&X]D!!?<&5PG%.E$O"KG@"CG-A4.5-XEG_19V889AM"#N1
MRLT"3R0E*^+'4=T? !%87QF^*L081$2>-5L$5N.@!0):#Q;B1:/3PO<>7KM"
MT8!,!WSR,(Q%V!S96^#989'(LQ@#'8"MS2(1%@+0SV4_Q YPHV!;]+HP/0&L
M16FVXZ3"KG1$^CD8$4A$(,V!L^'O60]@+J]""!7/QQ@JS(_TU >*D%28V*(R
M8#2FUE=PHVLDI ,6301QT#YS%$T\EB8PSC6.4JI R(.A"72!:@"@CV<-TDZ
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M8V+22+L];)[?O=1UKAX%-XRR4G#U8-DTRPK+_4F#\IDVRF940%! 4$!00%!
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MT \9TP@HP0MK\!OP"G6<"2QR$+((9W9\L)E@14 UWV'Z,=CD(/VF;QX!B&"
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M8QYD/RUT^BV-^Y.N;-9K$7U\R0JWIM5L3RT?;3J+0V//&HFPQ-2P07L,_XB
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M**VH^X!WU\3"748N$NJZ7"7<9,IRBMJ+9T:C<8G(O4#ZN\R !-\ELVUH(*G
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MRCM@ XID^I2@17EGF$!V/N*",4#R3GMQBZ8 "0,AGP'?C,7Z8%SL82XT=J6
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M[N$:D!?$O,+5AWU,,&(\U33IQ/X Y0QW^W$02G\#T)BTU)4)$*A(9PR=C!J
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M:J0*%#ZBK3(-/%A+F&NU6R<V=^(HUR]2A0[+LQ5=,X\=32HM;$X(S8:FE[;
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MH;6-W(="7F6?+D/K!DSTF;N@J=^S>W+KN]0#7J)>6'^@*)8R6&\5.('%O/X
MNLS_Q!FX_:\GW!KT&X;9,1DS6J;1T7N]7JO=U>VNT=)[#:K_G]EH/DF?&@53
MB3QD]7[ Z-<Z'<!;7U+GGD[".;0 3M)=ZAV @V*N1S#7?("NNR) E^P\V<MR
MGIM1J#LF-/'CL/CH-K6&WGT(.EH=K6$V-T+'-M_IFFZT'OCD\L7J/4UO[VG:
MSJ;3'MOZF=<V>K'Y74:O[[7#R5ON.!/1<O'&=V$#DQG[N^H[O&66[UG<X12M
M*VS7_MOU]4=RR\9^ -XKB7SRB3G,PM_?^UY=?'MM?XE#_.2--_ #5SYZ\:='
M8YO#QY<G!:&+5RC\@I!PC\"4#NPUK!'VS6(@K*?G[C:-:.'&Y[6!N: -"H"Q
M*.[7ATYVX9ZU*Q1=^SP*&"/O8-PH)*\]&^CQG6AHW=1K>P^['1 G58IX&@VC
MN47$J]0;,4H4NZU,]+13",W? C\,D3O!3B1U<AUF"N81X=&5+FO^4'AI<*\4
ML%DX@]MN7\<,5A9OJ%5K-IM:)@8.Q;$/*SRZJXJ7BAC+2HR=9D?KG1<Q'E]1
MS1F]IU(-5*G[36NF!8R&C(!WB)Z2$Z-Q#JZA&_[PM-5=X N%ZD.F5!V0$*Y=
M,/+X]RRVP+V(>D..D48:ABP*R<6-'T;X54@=%E[N3$ZWM=8&*RPXB4*I7&]J
M!5',/E T3O#DYPM^N74.V.D<1NM&Z\!% "L'(J-A'JWRZG$U?5-I^C*(_T,1
M^IQCGT:(S\FKWS"SMCJ.5/&&6C6SU=-TY64KXB@BCIYI:"WE]2JO]QQTX09!
M;AH2BJ>#>)R![DW [I@7LYT%OZM@&Q>#J=/6VJ4*QSU2_!P*;LNO$E2/!,"_
M5B2P2Q(X&6%]J.3H;23VO%=3]N#464>G.EW-K!:O%^^CDN)^"4K::_S&RJ.D
M+/=*TB=F,W*;L+N5B??M0QT*R"LIL=MG04A<.A%W4F IQ 9!&_DD\&-QE4Y;
MFDJ^N+.9K72RJP+IE7'#T,S.0??'M0/:-@;JB3P$9+;Y:WGH1NC2 YB0C ,.
MT.28W!J&OL4I9G3>\V@$-!A&(0Z'[[\R_'@<^'9LP8?4^B?F 7SB!\3A%O9#
MLLD@\%T2C7@  RF\CX6[1*"I=0Y+H+P,&,R2;8?"2'%7&RD!&V"2;@A88+-/
ML,% ? &#\3LJ4G==>!P)@(68;6<3VO?OV!8XV^C6QW9/J1L(Z@9"M?-T5>YT
M^7!2L91CE3M=G4C%H8(^V PF:4*I,J=/Y1BM>$-)8YE2A4;5F>[9$J/H?7->
MQ'A\-:7.D,]#V:_)G+ZPF?SM4B51ES&)>C9&U= :NDJL5HG5*K%Z[Z[EV216
M'WL951FYG>R7I-TH4 (% OWHY(Z^O^.#0 \)R'GNW;$T=H^1_7]B'DU(R*PX
MX'CH0BX^1",6)*UC?WAJ=J[8MS$>T5SNPEBHGK P#BPK*@>A9G?/V1)*/NP5
M?S=^$+!P[,OZLQ']EAWW720A0_@L9_V=%?M?&#W-7-BZ8OT$.KK1U/1#@:<L
MX11U/:T4CO4A[:?L[$1=3CN!6/6R/NUFN[FF3[LZR#A3XC!JS8ZQ)K"B#A9*
MI=Z4)MSU:=YKX1?P.^$1D(!&ZBH:!EPUO53GFZ5+A#_]JV@E*U17>0HX&<E\
MT)MHA>)9W3LKI2!9=GBWW[.[0^VCDK)]"4H:VEY;4!T?)2<C; ]F!A<U3-]I
M4FW9G/SMLA5+X\HO,=@ULUP)B;L-'2G:V>.RL2?[*=*.4@8/-KJ+E,'N3@G*
MQLW;A7M+P\W+VCVWC3.6S">%2^- N#RVI%3E&E2Y!E6NX<3+-63QNYF2#/G4
MK)U68E@J&C9JR"O0I[KQ'KMAZ#)-HKKQ;N9@Z>V"P/->NO&^Z/OV!/X91:[S
M\_\'4$L! A0#%     @ 6#B;5J[OP='$'P  0!<! !               ( !
M     &QL>2TR,#(S,#0R-RYH=&U02P$"% ,4    " !8.)M62J])/;D#  #[
M$0  $               @ 'R'P  ;&QY+3(P,C,P-#(W+GAS9%!+ 0(4 Q0
M   ( %@XFU911,5%* H  ,I,   4              "  =DC  !L;'DM,C R
M,S T,C=?9&5F+GAM;%!+ 0(4 Q0    ( %@XFU;\_\)CY!   -^D   4
M          "  3,N  !L;'DM,C R,S T,C=?;&%B+GAM;%!+ 0(4 Q0    (
M %@XFU:S8"^RP0D  %Q1   4              "  4D_  !L;'DM,C R,S T
M,C=?<')E+GAM;%!+ 0(4 Q0    ( %@XFU:;(<< M4    =5 P >
M      "  3Q)  !Q,3(S;&EL;'ES86QE<V%N9&5A<FYI;F=S<"YH=&U02P4&
2      8 !@". 0  +8H

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
